Interestingly, and in sharp contrast to KMT2A-r models, BCL-2+BCR::ABL1 mutated samples did not respond to VEN application, with similar blast kinetics and tumor cell frequencies in controls and treated animals (Fig. 7A, B, lower panels). The gene discussed is BCL2; the disease is neoplasm.